Most important take away

ARK Invest argues that the convergence of multiomics data, AI, and gene editing is creating a virtuous cycle that will dramatically reshape drug development and healthcare economics. The most striking claim is that an AI-accelerated curative therapy in Phase I testing could be worth over $2 billion per drug, and a single gene-editing treatment for cardiovascular disease could address a $2.8 trillion market — dwarfing even the best-selling drugs in history.

Chapter Summaries

What Is Multiomics

Multiomics captures biology across five core layers — genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Rather than studying one layer in isolation, multiomics integrates them to form a systems-level view of health and disease. Innovation is happening simultaneously across the entire biological stack.

The AI-Multiomics Flywheel

AI and biological data generation form a reinforcing cycle: cheaper multiomics tools produce more data, better AI models emerge, which then improve diagnostics, drug design, and therapeutics, generating even richer data in return. ARK organizes this around four areas: multiomics tools, molecular diagnostics, AI-developed drugs, and cures.

Declining Costs and Exploding Data Volumes

Genome sequencing has dropped from $2.7 billion (Human Genome Project) to roughly $100 today and could reach $10 by 2030. Next-gen molecular diagnostic test volumes are projected to more than double by decade’s end, and the biological data generated annually now rivals the token volumes used to train frontier LLMs, with a 10x increase expected by 2030.

AI in Diagnostics and Drug Development

AI-enabled FDA approvals have inflected upward since late 2022, projected to rise from about 10% to 30% of diagnostics and devices by 2030. AI-driven drug development could cut time to market by roughly 40% and reduce costs by about 4x, potentially generating $3 billion in cumulative cash flow before a traditional drug even breaks even.

Functional Cures and Gene Editing

Functional cures — one-time or limited-course therapies that durably eliminate disease — can be up to 20x more valuable than typical drugs because they front-load revenue. ARK highlights hereditary angioedema gene editing (lifetime disease costs of $10-20M per patient) and in-vivo gene editing for cardiovascular disease, which targets a $2.8 trillion addressable market at a value-based price of $165,000 per patient.

Longevity as a Scientific Target

Advances in molecular clocks and biological measurement are making aging a tractable scientific target. ARK estimates the US longevity opportunity at $1.2 quadrillion based on quality-adjusted life years, framing it not as a forecast but as a value framework similar to estimating the economic potential of electricity before it was fully harnessed.

Summary

Actionable Insights and Investment Themes:

1. Genome sequencing cost collapse creates volume growth. As sequencing approaches $10 per genome by 2030, diagnostic test volumes will more than double. Companies providing sequencing tools and next-gen molecular diagnostics stand to benefit from massive volume expansion.

2. AI-driven drug development is an economic game-changer. AI can reduce drug development timelines by ~40% and costs by ~4x. An AI-developed drug could accumulate roughly $3 billion in cash flow before a traditional competitor breaks even. This favors biotech and pharma companies integrating AI into their pipelines early.

3. Curative gene-editing therapies command premium pricing. One-time cures for rare diseases could be priced above $1 million per patient (roughly 15x lifetime chronic treatment costs) and may be up to 20x more valuable than traditional drugs. Companies advancing gene-editing cures, particularly those in late-stage clinical development, represent high-value opportunities.

4. Cardiovascular gene editing is the blockbuster opportunity. A one-time gene-editing therapy for atherosclerotic cardiovascular disease could address a $2.8 trillion total addressable market in the US alone (17 million patients at $165,000 each). Even capturing a fraction of this market would rival cumulative Lipitor sales over 20 years.

5. AI-accelerated cures dramatically increase early-stage asset value. ARK models that a Phase I AI-accelerated curative therapy could be worth more than $2 billion per drug, a substantial re-rating of early-stage biotech assets that historically had near-zero expected value.

6. Longevity is becoming investable. Improved biological aging measurement (molecular clocks, proteomic signals) is turning aging from a speculative concept into a tractable scientific target. ARK frames the US longevity market at $1.2 quadrillion, dependent on convergence across multiomics, AI, and robotics.

Stocks and Investments Mentioned: No specific stock tickers were called out. ARK noted that many companies operate across different biological layers (genomics, proteomics, etc.) building tools, diagnostics, and therapeutics, but deliberately focused on the broader theme rather than individual names. The presentation is part of ARK Invest’s Big Ideas 2026 research series, which aligns with their funds focused on genomic revolution and disruptive innovation.